Articles By Melissa Akselrad, MD
CAR T Gets the Spotlight. Are We Missing the B Cells That Matter?
CAR T is having its moment in rheumatology. But William Robinson’s presentation at ACR Convergence 2026 raised a question I find even more compelling: are we failing to eliminate the right B cells with therapies we already have?
Read Article
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment?
We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting our ability to treat them effectively.
Read Article
Lupus CVD: Beyond the Lipid Panel
Innate immune dysregulation drives premature atherosclerosis in SLE, and it explains much of the cardiovascular risk that Framingham factors and medications do not. The main driver is a self-amplifying loop between type I interferon (IFN) and neutrophil extracellular traps (NETs).
Read Article
Valves Gone Wild in SLE
Lupus valvulitis is a rare cardiac manifestation of active systemic lupus erythematosus (SLE) and is defined by inflammation of one or more cardiac valves. It is often associated with Libman-Sacks endocarditis, which is characterized by the presence of sterile vegetations on the heart valves.
Read Article
